Proactive Cancer Screening
For Men. Early. Decisive.

An 11-marker male tumour marker panel screening for prostate, testicular, colorectal, pancreatic, gastric, and bladder cancer biomarkers.

Tumour markers cannot diagnose cancer on their own, but elevated markers trigger the imaging and investigation that finds cancers early, when outcomes are best. The Tumor Marker Male panel covers the 11 most clinically validated cancer biomarkers in menincluding PSA for prostate cancer, AFP and beta-HCG for testicular cancer, and CEA and CA 19-9 for gastrointestinal malignancies.

Many of these markers are elevated months or years before clinical symptoms appear. Annual monitoring enables detection of rising trends, which is clinically more significant than a single elevated value.